Cardiac Amyloidosis
79
28
30
16
Key Insights
Highlights
Success Rate
76% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
6.3%
5 terminated out of 79 trials
76.2%
-10.4% vs benchmark
10%
8 trials in Phase 3/4
25%
4 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 16 completed trials
Clinical Trials (79)
Cardiovascular Multimodality Imaging Study
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
Test-retest Study With [18F]FBB in Cardiac Amyloidosis
Detection of Cardiac Amyloidosis Using Right Ventricular Sensing Amplitude in Patients With Left Ventricular Hypertrophy
N-of-1 for Beta-Blockers in Cardiac Amyloidosis
AI Echocardiographic Screening of Cardiac Amyloidosis
Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study
124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome
[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy
Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy
Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis
PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY
Prevalence of Cardiac Thrombi in Cardiac Amyloidosis
AI-based Echocardiography for Detection of Cardiac Amyloidosis
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
Fast Cardiac Bone SPECT-CZT in Transthyretin Cardiac Amyloidosis
Cardiac Amyloidosis in HFpEF Tunisian Patients
Retrospective Identification of Scintigraphic Cardiac Amyloidosis (RISCA)
Elevated Rate Pacing of Cardiac Amyloidosis